Purchase this article with an account.
M. K. Webster, B. A. Blodi, J. A. Elledge, R. P. Danis, ANCHOR Study Group; Angiographic Results of the ANCHOR Study of Ranibizumab in Neovascular Age-Related Macular Degeneration: Reading Center Evaluation of Angiographic Data. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4583.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the 12 and 24 month angiographic outcomes, compared to baseline, from the ANCHOR study of ranibizumab in subjects with subfoveal, predominantly classic, choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), and to compare these outcomes with ranibizumab to those treated with verteporfin.
Retrospective analyses of angiographic data from 423 patients enrolled in ANCHOR. Morphologic outcomes were evaluated from fluorescein angiograms and color photographs using a modified MPS grading protocol. Recorded abnormalities include area of classic and occult CNV, fibrous tissue, disciform scar, atrophic scar, total lesion area, SSR, and fluorescein leakage, as well as presence of involuted neovascular lesion.Pre-specified secondary endpoints were the mean change from baseline in the total area of CNV and in the total area of leakage from CNV at month 12 and 24. Pre-specified exploratory endpoints included mean change from baseline in the total area of CNV, the total area of the lesion and in the area of serous sensory retinal detachment at months 12 and 24. Exploratory outcome measures included proportion of patients with no leakage from CNV and mean change from baseline in the area of subretinal fibrous tissue/disciform scar.
M12 results have shown statistically significant benefits of ranibizumab for the mean change in CNV size, the area of the CNV lesion and leakage.
Predominantly classic lesions in subjects treated with ranibizumab demonstrated improvement in FA outcomes compared with subjects treated with verteporfin.
This PDF is available to Subscribers Only